JP2011530535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011530535A5 JP2011530535A5 JP2011522277A JP2011522277A JP2011530535A5 JP 2011530535 A5 JP2011530535 A5 JP 2011530535A5 JP 2011522277 A JP2011522277 A JP 2011522277A JP 2011522277 A JP2011522277 A JP 2011522277A JP 2011530535 A5 JP2011530535 A5 JP 2011530535A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- disease
- composition
- vasculitis
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 17
- 230000003463 hyperproliferative effect Effects 0.000 claims description 14
- 206010047115 Vasculitis Diseases 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 201000007455 central nervous system cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 208000000649 small cell carcinoma Diseases 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 208000037804 stenosis Diseases 0.000 claims description 4
- 230000036262 stenosis Effects 0.000 claims description 4
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 claims description 2
- 206010051341 Bile duct stenosis Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000036495 Gastritis atrophic Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 208000000592 Nasal Polyps Diseases 0.000 claims description 2
- 206010068786 Overlap syndrome Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010036774 Proctitis Diseases 0.000 claims description 2
- 206010036783 Proctitis ulcerative Diseases 0.000 claims description 2
- 206010037549 Purpura Diseases 0.000 claims description 2
- 241001672981 Purpura Species 0.000 claims description 2
- 206010039705 Scleritis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 201000010001 Silicosis Diseases 0.000 claims description 2
- 241000272534 Struthio camelus Species 0.000 claims description 2
- 208000031737 Tissue Adhesions Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 206010003441 asbestosis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 230000004154 complement system Effects 0.000 claims description 2
- 208000018631 connective tissue disease Diseases 0.000 claims description 2
- 230000003210 demyelinating effect Effects 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000001198 duodenum Anatomy 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims description 2
- 208000001875 irritant dermatitis Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 208000016366 nasal cavity polyp Diseases 0.000 claims description 2
- 208000012028 nasolacrimal duct disease Diseases 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 208000004235 neutropenia Diseases 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 206010035653 pneumoconiosis Diseases 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 210000000653 nervous system Anatomy 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- ABGCNXRYIJEOAK-UHFFFAOYSA-N CC1=CC2OC2OC1 Chemical compound CC1=CC2OC2OC1 ABGCNXRYIJEOAK-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8701008P | 2008-08-07 | 2008-08-07 | |
| US61/087,010 | 2008-08-07 | ||
| PCT/US2009/053159 WO2010017480A1 (en) | 2008-08-07 | 2009-08-07 | Glycoside compounds and pharmaceutical compositions thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011530535A JP2011530535A (ja) | 2011-12-22 |
| JP2011530535A5 true JP2011530535A5 (OSRAM) | 2013-05-02 |
Family
ID=41663995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011522277A Pending JP2011530535A (ja) | 2008-08-07 | 2009-08-07 | グリコシド化合物およびその医薬組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US8361973B2 (OSRAM) |
| EP (1) | EP2320729B1 (OSRAM) |
| JP (1) | JP2011530535A (OSRAM) |
| WO (1) | WO2010017480A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010017480A1 (en) | 2008-08-07 | 2010-02-11 | Centrose, Llc | Glycoside compounds and pharmaceutical compositions thereof |
| US8470980B2 (en) | 2009-09-09 | 2013-06-25 | Centrose, Llc | Extracellular targeted drug conjugates |
| WO2011085641A1 (en) | 2010-01-15 | 2011-07-21 | Suzhou Neupharma Co., Ltd. | Certain chemical entities, compositions, and methods |
| US9493503B2 (en) | 2011-02-02 | 2016-11-15 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| JP2014510080A (ja) * | 2011-03-09 | 2014-04-24 | セントローズ， エルエルシー | 細胞外標的化薬物複合体 |
| WO2013165924A1 (en) | 2012-04-29 | 2013-11-07 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2014018625A1 (en) | 2012-07-25 | 2014-01-30 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| WO2017023760A1 (en) | 2015-07-31 | 2017-02-09 | Prudent James R | Extracellular drug conjugates targeting cd20 |
| JP6603551B2 (ja) * | 2015-11-11 | 2019-11-06 | 花王株式会社 | 毛成長抑制剤 |
| GB2611864B (en) | 2019-08-23 | 2023-12-06 | Imagination Tech Ltd | Random accessible image data compression |
| WO2021054978A1 (en) * | 2019-09-20 | 2021-03-25 | Pollard Bette Silver | Cardiac cardenolides to reduce fibrosis and enhance epithelial differentiation |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3987031A (en) * | 1970-12-23 | 1976-10-19 | Boehringer Ingelheim Gmbh | Acyl derivatives of proscillaridin a |
| DE2254060A1 (de) * | 1972-11-04 | 1974-05-16 | Hoechst Ag | Cardenolid-3-eckige klammer auf 4'-amino-2',3',4'-tridesoxy-glykoside eckige klammer zu und verfahren zu ihrer herstellung |
| DE2319874C2 (de) * | 1973-04-19 | 1983-06-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue Derivate des Digitoxigenin-α-L-arabinosids, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| IT1147806B (it) * | 1981-01-23 | 1986-11-26 | Wellcome Found | Complessi di ciclodestrine e glicosidi cardiaci per uso terapeutico e procedimento di preparazione |
| GB8600491D0 (en) * | 1986-01-09 | 1986-02-12 | Erba Farmitalia | Aminoglycoside norcholanic acid derivatives |
| US5280113A (en) | 1989-08-16 | 1994-01-18 | Monsanto Company | Method for producing synthetic N-linked glycoconjugates |
| JP3826235B2 (ja) * | 1994-06-10 | 2006-09-27 | 松森 昭 | 炎症性サイトカイン分泌抑制剤 |
| US5668272A (en) * | 1995-06-30 | 1997-09-16 | National Research Council Of Canada | Method for producing synthetic N-linked glycoconjugates |
| US6180612B1 (en) * | 1997-10-31 | 2001-01-30 | The University Of Virginia Patent Foundation | Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives |
| JP2002536415A (ja) * | 1999-02-12 | 2002-10-29 | セルパス インコーポレイテッド | 抗腫瘍療法 |
| AU2001282088A1 (en) * | 2000-08-17 | 2002-02-25 | Terness, Peter | Immunosuppressive, antiinflammatory and analgetic compounds |
| US20030031677A1 (en) | 2001-06-25 | 2003-02-13 | Drug Innovation & Design, Incorporated | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications |
| US20050026849A1 (en) * | 2003-03-28 | 2005-02-03 | Singh Chandra U. | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases |
| BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
| WO2006002381A1 (en) * | 2004-06-24 | 2006-01-05 | Wisconsin Alumni Research Foundation | Neoglycorandomization and digitoxin analogs |
| JP2007008879A (ja) * | 2005-06-30 | 2007-01-18 | Yanbaru Green Health:Kk | 抗腫瘍剤及びこれを含有する食品 |
| US7402325B2 (en) * | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| MX2008008608A (es) * | 2006-01-09 | 2009-03-04 | Btg Int Ltd | Moduladores de factor i inducible por hipoxia y usos relacionados. |
| AU2007269714A1 (en) | 2006-07-03 | 2008-01-10 | Charles David Adair | Composition for modulating the expression of cell adhesion molecules |
| US20100154071A1 (en) | 2007-03-28 | 2010-06-17 | Novartis Ag | Fxdy5 modulators for treating, diagnosing, and detecting cancer |
| WO2010017480A1 (en) | 2008-08-07 | 2010-02-11 | Centrose, Llc | Glycoside compounds and pharmaceutical compositions thereof |
-
2009
- 2009-08-07 WO PCT/US2009/053159 patent/WO2010017480A1/en not_active Ceased
- 2009-08-07 EP EP20090805612 patent/EP2320729B1/en active Active
- 2009-08-07 US US13/057,961 patent/US8361973B2/en active Active
- 2009-08-07 JP JP2011522277A patent/JP2011530535A/ja active Pending
-
2012
- 2012-12-27 US US13/728,639 patent/US8703723B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011530535A5 (OSRAM) | ||
| TWI515184B (zh) | 紫杉烷衍生物製備改良方法 | |
| CN102532235B (zh) | 蟾毒配基衍生物及其制备方法、包含该衍生物的组合物、及其用途 | |
| JP2013503174A5 (OSRAM) | ||
| TN2010000256A1 (en) | Organic compound | |
| MX2008016134A (es) | Derivados de fenol para el tratamiento de enfermedades respiratorias. | |
| JP2010514787A5 (OSRAM) | ||
| JP2016506916A5 (OSRAM) | ||
| JP2011526244A5 (OSRAM) | ||
| CN110478487B (zh) | 一种大环内酯化合物在逆转肿瘤多药耐药增强抗肿瘤疗效方面的应用 | |
| EP3464309A1 (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
| JP2014528931A (ja) | カバジタキセルの結晶形 | |
| WO2012065079A4 (en) | Methods of treating cancer | |
| Fan et al. | Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition | |
| JP2017502984A5 (OSRAM) | ||
| JP2016502981A5 (OSRAM) | ||
| JP2018521969A (ja) | 医薬用共結晶及びその用途 | |
| JP2019524852A5 (OSRAM) | ||
| Jiang et al. | Discovery of a novel chimeric ubenimex–gemcitabine with potent oral antitumor activity | |
| WO2023282269A1 (ja) | パーキンソン病の予防又は治療薬 | |
| Huang et al. | Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors | |
| Quiñonero et al. | Combining olaparib and ascorbic acid on nanoparticles to enhance the drug toxic effects in pancreatic cancer | |
| Gonzalez-Sabin et al. | Exploring novel opportunities for aureolic acids as anticancer drugs | |
| RU2010150964A (ru) | Произведенные из свр501 агенты и способы на их основе для ингибирования остановки клеточного цикла g2 и сенсибилизации клеток к повреждающим днк агентам | |
| Yu et al. | Discovery of oral chemotherapeutic reversal agents for treating multidrug resistance cancer |